Eli Lilly Bolsters Genetic Medicine Portfolio Through Strategic Acquisition of Orna Therapeutics
Eli Lilly and Company has announced a definitive agreement to acquire Orna Therapeutics in a transaction valued at approximately 2.4 billion dollars,
by 
Josh Weiner
Josh Weiner